An update on pegylated IFN-α2b for the adjuvant treatment of melanoma

Expert Review of Anticancer Therapy

Volumn 12, Issue 11, 2012, Pages 1449-1459

  Agarwala, Sanjiv S ^a  

^a St Luke's Cancer Center   (United States)

Author keywords

adjuvant therapy; interferon; melanoma; pegylated IFN a2b; pharmacokinetics; quality of life; ulceration

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CHILL; DEPRESSION; DIAPHORESIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXCISION; FATIGUE; FEVER; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEADACHE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALAISE; MELANOMA; MENTAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIMARY TUMOR; PROGNOSIS; RECURRENCE RISK; REVIEW; RIGOR; SIDE EFFECT; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERON-ALPHA; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84871270481     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.120     Document Type: Review

References (49)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
3. Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
4. Balch CM, Gershenwald JE, Soong SJ et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J. Clin. Oncol. 28(14), 2452-2459 (2010).
5. McMasters KM, Edwards MJ, Ross MI et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann. Surg. 252(3), 460-465; discussion 465 (2010).
6. Eggermont AM, Spatz A, Lazar V, Robert C. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr. Opin. Oncol. 24(2), 137-140 (2012).
7. Wang W, Edington HD, Rao UN et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNa2b. Clin. Cancer Res. 13(5), 1523-1531 (2007).
8. Wang W, Edington HD, Rao UN et al. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin. Cancer Res. 14(24), 8314-8320 (2008).
9. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18(12), 2444-2458 (2000).
10. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001).
11. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
12. Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy: melanoma. J. Skin Cancer 2011, 274382 (2011).
13. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 102(7), 493-501 (2010).
14. Pehamberger H, Soyer HP, Steiner A et al.; French Cooperative Group on Melanoma. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 16(4), 1425-1429 (1998).
15. Grob JJ, Dreno B, de la Salmonière P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351(9120), 1905-1910 (1998).
16. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358(9285), 866-869 (2001).
17. Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant lowdose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22(1), 53-61 (2004).
18. Eggermont AM, Suciu S, MacKie R et al.; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366(9492), 1189-1196 (2005).
19. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670-1677 (2004).
20. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials. Cancer Treat. Rev. 29(4), 241-252 (2003).
21. Guadagnolo BA, Zagars GK. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. Lancet Oncol. 10(4), 409-416 (2009).
22. Beadle BM, Guadagnolo BA, Ballo MT et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 73(5), 1376-1382 (2009).
23. Burmeister B, Henderson MA, Thompson JF. Adjuvant radiotherapy improves regional (lymph node field) control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (TROG 02.01/ANZMTG 01.02). Int. J. Radiat. Oncol. Biol. Phys. 75(Suppl.), S2 (2009).
24. Finkelstein SE, Trotti A, Rao N et al. The Florida Melanoma Trial I: a prospective multicenter Phase I/II trial of postoperative hypofractionated adjuvant radiotherapy with concurrent interferon-alfa-2b in the treatment of advanced stage III melanoma with long-term toxicity follow-up. ISRN Immunology 2012, 324235 (2012).
25. Hazard LJ, Sause WT, Noyes RD. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int. J. Radiat. Oncol. Biol. Phys. 52(3), 796-800 (2002).
26. Gyorki DE, Ainslie J, Joon ML, Henderson MA, Millward M, McArthur GA. Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma - a retrospective single centre study. Melanoma Res. 14(3), 223-230 (2004).
27. Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr. Drug Metab. 13(1), 105-119 (2012).
28. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferonalpha?2b formulation. Cancer 95(2), 389-396 (2002).
29. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68(5), 556-567 (2000).
30. Daud AI, Xu C, Hwu WJ et al. Pharmacokinetic/ pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother. Pharmacol. 67(3), 657-666 (2011).
31. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon ?-2b plus ribavirin compared with interferon ?-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001).
32. Lindsay KL, Trepo C, Heintges T et al.; Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon ?-2b to interferon ?-2b as initial treatment for chronic hepatitis C. Hepatology 34(2), 395-403 (2001).
33. Eggermont AM, Bouwhuis MG, Kruit WH et al. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized Phase III trial (EORTC 18991). Cancer Chemother. Pharmacol. 65(4), 671-677 (2010).
34. Bukowski R, Ernstoff MS, Gore ME et al. Pegylated interferon ?-2b treatment for patients with solid tumors: a Phase I/II study. J. Clin. Oncol. 20(18), 3841-3849 (2002).
35. Eggermont AM, Suciu S, Santinami M et al.; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon ?-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet 372(9633), 117-126 (2008).
36. Eggermont AM, Suciu S, Santinami M et al. EORTC 18991 Phase III trial: Long-term adjuvant pegylated interferon- ?2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. J. Clin. Oncol. 29 (2011) (Abstract 8506b).
37. Wheatley K, Ives N, Eggermont AM, Kirkwood JM, Cascinelli N, Markovic SN. Interferon-? as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 8526).
38. Eggermont AM, Suciu S, Testori A et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the Phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer 48(2), 218-225 (2012).
39. Hansson J, Aamdal S, Bastholt L et al.; Nordic Melanoma Cooperative Group. Two different durations of adjuvant therapy with intermediate-dose interferon ?-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised Phase 3 trial. Lancet Oncol. 12(2), 144-152 (2011).
40. Grob JJ, Jouary T, Dreno B et al. Adjuvant therapy with pegylated interferon ?-2b (36 months) versus low-dose interferon ?-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. J. Clin. Oncol. 28(18 Suppl.) (2010) (Abstract LBA8506).
41. Carrat F, Bani-Sadr F, Pol S et al.; ANRS HCO2 RIBAVIC Study Team. Pegylated interferon ?-2b vs standard interferon ?-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292(23), 2839-2848 (2004).
42. Hauschild A, Gogas H, Tarhini A et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112(5), 982-994 (2008).
43. Bottomley A, Coens C, Suciu S et al. Adjuvant therapy with pegylated interferon ?-2b versus observation in resected stage III melanoma: a Phase III randomized controlled trial of healthrelated quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 27(18), 2916-2923 (2009).
44. Brandberg Y, Aamdal S, Bastholt L et al. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic Phase 3 trial with adjuvant intermediate-dose interferon ?-2b. Eur. J. Cancer 48(13), 2012-2019 (2012).
45. Agarwala SS, Lee SJ, Flaherty LE et al. Randomized Phase III trial of high-dose interferon ?-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 8505).
46. American Cancer Society. Cancer facts and figures 2012. www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/ document/acspc-031941.pdf
47. National Comprehensive Cancer Network. NCCN clinical practice guidelines. Melanoma. Version 3.2012. www.nccn.org
48. Schering Corporation. SYLATRON™ (peginterferon alfa-2b) prescribing information. www.merck.com/product/usa/pi- circulars/s/sylatron/sylatron-pi.pdf
49. ClinicalTrials.gov. Adjuvant PEG Intron in Ulcerated Melanoma. http://clinicaltrials.gov/ct2/show/NCT015 02696?term=NCT01502696&rank=1